Drotrecogin alfa (activated): a novel therapeutic strategy for severe sepsis

Pastores, S.M.
January 2003
Postgraduate Medical Journal;Jan2003, Vol. 79 Issue 927, p5
Academic Journal
journal article
Recent studies have highlighted the close link between activation of the coagulation system and the inflammatory response in the pathophysiology of severe sepsis. The protein C anticoagulant pathway plays an integral part in modulating the coagulation and inflammatory responses to infection. In patients with sepsis, endogenous protein C levels are decreased, shifting the balance toward greater systemic inflammation, coagulation, and cell death. On the basis of a single large randomised phase 3 trial, drotrecogin alfa (activated), a recombinant form of human activated protein C, was recently approved for the treatment of adult patients with severe sepsis and a high risk of death. Since its approval, several questions have been raised regarding the appropriate use of this agent. Given the increased risk of serious bleeding and the high cost of treatment, drotrecogin alfa (activated) should be reserved at this time for the most acutely ill patients with severe sepsis who meet the criteria that were used in the phase 3 trial.


Related Articles

  • Anticoagulation in sepsis: is low-dose heparin as effective as activated protein C? Agarwal, Ritesh; Gupta, Dheeraj // Intensive Care Medicine;Sep2005, Vol. 31 Issue 9, p1297 

    Presents a letter to the editor commenting on the effectiveness of low-dose heparin as activated protein C in anticoagulation in sepsis.

  • Advances in Sepsis Therapy. Glück, Thomas; Opal, Steven M. // Drugs;2004, Vol. 64 Issue 8, p837 

    During the past 3 years new insights have been gained into the fundamental elements that underlie the pathogenesis of sepsis, and after years of frustrating failures, progress in the basic understanding of sepsis has translated into successful new therapies. These new treatment strategies have...

  • Protein C anticoagulant system-anti-inflammatory effects. Esmon, Charles // Seminars in Immunopathology;Mar2012, Vol. 34 Issue 1, p127 

    Activated protein C (APC) plays active roles in preventing progression of a number of disease processes. These include thrombosis due to its direct anticoagulant activity which is likely augmented by its cytoprotective activity, thereby limiting exposure of procoagulant cellular membrane...

  • Concurrent administration of heparin and activated protein C in a patient with pulmonary embolism and severe sepsis with positive outcome. Juneja, Deven; Mohan, S.; Veturi, Vivek V.; Gopal, Palepu B. // Indian Journal of Critical Care Medicine;Jul-Sep2009, Vol. 13 Issue 3, p163 

    Results of the PROWESS trial suggested that heparin may reduce the efficacy of recombinant human activated protein C (rhAPC) and the XPRESS study also showed increased bleeding complications in patients receiving heparin with rhAPC. Although it has been shown that heparin prophylaxis may be used...

  • Drotrecogin Alfa (activated) in severe sepsis and septic shock. Hussain, Aziza Muhammad // Anaesthesia, Pain & Intensive Care;Jul-Sep2011, Vol. 15 Issue 2, p79 

    The author reflects on the use of Drotrecogin alfa (activated) in managing severe sepsis and septic shock. He cites that this drug is a recombinant form of the natural anticoagulant activated protein C (rhAPC) used in treating patients with severe sepsis who are at risk of death. The author also...

  • Counteracting clotting in sepsis. Kahn, Mark L. // Nature Medicine;Sep2008, Vol. 14 Issue 9, p918 

    The article focuses on the study of sepsis and coagulation syndrome treated with activated protein C (APC), anticoagulant generated on the endothelial cell surface that is now a standard therapy for severely ill patients with sepsis. It establishes principles that coagulation enzymes can...

  • Prevalence of Serious Bleeding Events and Intracranial Hemorrhage in Patients Receiving Activated Protein C: A Systematic Review and Meta-analysis. Khan, Ajmal; Agarwal, Ritesh; Aggarwal, Ashutosh N.; Gupta, Dheeraj // Respiratory Care;Jul2010, Vol. 55 Issue 7, p901 

    BACKGROUND: Activated protein C reduces 28-day mortality in patients with severe sepsis, but its anticoagulant properties entail a risk of bleeding. OBJECTIVE: The aim of this systematic review was to evaluate the prevalence of serious bleeding events in patients receiving activated protein C....

  • Thrombomodulin: A Bifunctional Modulator of Inflammation and Coagulation in Sepsis. Takayuki Okamoto; Hironobu Tanigami; Koji Suzuki; Motomu Shimaoka // Critical Care Research & Practice;2012, p1 

    Deregulated interplay between inflammation and coagulation plays a pivotal role in the pathogenesis of sepsis. Therapeutic approaches that simultaneously target both inflammation and coagulation hold great promise for the treatment of sepsis. Thrombomodulin is an endogenous anticoagulant protein...

  • Benefit-risk assessment of drotrecogin alfa (activated) in the treatment of sepsis. De Backer, Daniel // Drug Safety;2007, Vol. 30 Issue 11, p995 

    Severe sepsis is a common cause of death in critically ill patients. Several mechanisms have been implicated in the development of organ dysfunction in patients with severe sepsis. Among these, activation of inflammation and coagulation, together with endothelial dysfunction, seem to be major...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics